Equillium (LTS:0A4D) Accounts Payable & Accrued Expense : $5.86 Mil (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Equillium Accounts Payable & Accrued Expense?

Equillium's quarterly accounts payable & accrued expense declined from Sep. 2024 ($8.72 Mil) to Dec. 2024 ($6.16 Mil) and declined from Dec. 2024 ($6.16 Mil) to Mar. 2025 ($5.86 Mil).

Equillium's annual accounts payable & accrued expense increased from Dec. 2022 ($11.22 Mil) to Dec. 2023 ($11.40 Mil) but then declined from Dec. 2023 ($11.40 Mil) to Dec. 2024 ($6.16 Mil).

Equillium Accounts Payable & Accrued Expense Historical Data

The historical data trend for Equillium's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Equillium Accounts Payable & Accrued Expense Chart

Equillium Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

5.58

7.11

11.22

11.40

6.16

Equillium Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															8.42	11.39	8.72	6.16	5.86

Equillium Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Equillium Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Equillium Inc (LTS:0A4D) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

EQ:USA 0FY:Germany

Address

2223 Avenida De La Playa, Suite 105, La Jolla, CA, USA, 92037

Website

https://www.equilliumbio.com

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Equillium Headlines

No Headlines